Arformoterol Tartrate



Arformoterol Tartrate





(ar for moh’ ter ol)

Brovana

PREGNANCY CATEGORY C


Drug Classes

Beta2-adrenergic agonist, long-acting

Bronchodilator


Therapeutic Actions

Long-acting agonist that binds to beta2-adrenergic receptors in the lungs, causing
bronchodilation; also inhibits release of inflammatory mediators in the lungs, blocking swelling and inflammation.


Indications



  • Long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema



Contraindications and Cautions



  • Contraindicated with allergy to any component of the drug, acutely deteriorating COPD, acute bronchospasm, asthma without the use of a long-term control medication.


  • Use cautiously with CV disease, convulsive disorders, thyrotoxicosis, pregnancy, lactation.


Available Forms

Inhalation solution—7.5 mcg/mL


Dosages

Adults

15 mcg bid (morning and evening) by nebulization. Do not exceed total daily dose of 30 mcg.

Pediatric patients

Safety and efficacy not established.

Tags:
Jul 20, 2016 | Posted by in NURSING | Comments Off on Arformoterol Tartrate

Full access? Get Clinical Tree
Get Clinical Tree app for offline access